Anil Kumar Jaiswal (0000-0002-8169-0335)

Personal information

Biography

Anil Kumar Jaiswal is originally from India, he earned his undergraduate degree in Biology and Master’s in Biotechnology from Gorakhpur University, India, and he received his Ph.D. from Central Drug Research Institute/Jawaharlal Nehru University in life science in India. His research was focused on development of recombinant heat shock proteins as vaccine against visceral leismaniasis (Kala-azar). During his Ph.D. tenure, he also developed DsRed transgenic based drug screening model against visceral leishmaniasis using flow cytometry. He then started his postdoctoral training with Abdel Hamad at Johns Hopkins University, School of Medicine in Baltimore, Maryland, USA. His research is focused on the role syndecan-1 (Sdc-1) in homeostasis of IL-17 producing Natural Killer T17 cells in autoimmunity.

Activities

Collapse all

BioLegend (United States): San Diego, California, US

2021-07-26 to present | Scientist III (Product Development (Cell Analysis))

Employment

Anil Kumar Jaiswal

https://orcid.org/0000-0002-8169-0335

Personal information

Other IDs

Keywords

Countries

Biography

Activities

Employment (3)

BioLegend (United States): San Diego, California, US

Auburn University: Auburn, AL, US

Johns Hopkins University: Baltimore, Maryland, US

Education and qualifications (1)

Jawaharlal Nehru University: New Delhi, Delhi, IN

Works (31)

IFN-λ Regulates Neutrophil Biology to Suppress Inflammation in Herpes Simplex Virus-1–Induced Corneal Immunopathology

Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis.

Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani.

Syndecan-1-coating of interleukin-17-producing natural killer T cells provides a specific method for their visualization and analysis.

Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani.

Development of Leishmania donovani stably expressing DsRed for flow cytometry-based drug screening using chalcone thiazolyl-hydrazone as a new antileishmanial target.

Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.

Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.

Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies.

Development of 4-sulfated N-acetyl galactosamine anchored chitosan nanoparticles: A dual strategy for effective management of Leishmaniasis.

Syndecan-1 identifies and controls the frequency of IL-17-producing naïve natural killer T (NKT17) cells in mice.

Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Th1 immune response.

Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies.

Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapy.

Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis.

Antigen presenting cells targeting and stimulation potential of lipoteichoic acid functionalized lipo-polymerosome: a chemo-immunotherapeutic approach against intracellular infectious disease.

Immunological consequences of stress-related proteins--cytosolic tryparedoxin peroxidase and chaperonin TCP20--identified in splenic amastigotes of Leishmania donovani as Th1 stimulatory, in experimental visceral leishmaniasis.

Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B.

Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.

Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles.

Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.

Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation.

Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis.

Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules.

Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis

Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis.

Identification of novel S-adenosyl-L-homocysteine hydrolase inhibitors through homology-model-based virtual screening, synthesis, and biological evaluation.

Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.

Design and development of Amphotericin B bearing polycaprolactone microparticles for macrophage targeting.

Development and characterization of doxorubicin loaded microparticles against experimental visceral leishmaniasis.

Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening.

Peer review (31 reviews for 6 publications/grants)